Richard Kranitz Joins GenoMed, Inc. as a Member of its Board of Directors and as Corporate Secretary
SARASOTA, Fla.--(BUSINESS WIRE)--Dec. 13, 2001--GenoMed Inc. (``the Company'' or ``GenoMed'') (Pink Sheets:GMED), a St. Louis based medical genomics biotechnology company, announced today that Richard Kranitz has accepted a position as a member of the Company's Board of Directors and as Corporate Secretary.
Richard Kranitz, an attorney in private practice since 1970, is a 1969 graduate of the University of Wisconsin Law School and served for a year as an assistant to a federal judge. During the past 30 years he has served as a director of a number of private companies, and professional, civic, and charitable organizations. Since 1990, Mr. Kranitz has been a director of the Grafton State Bank, a subsidiary of Merchants & Manufacturers Bancorporation (symbol:MMBI). He has also served as a director of, among other public companies, Harp & Eagle, Ltd. (symbol:HARP) and Mentor Capital Consultants, Inc. (symbol:MCAP). Mr. Kranitz has served for a number of years as a director of the Mental Health of Ozaukee County, Inc., a non-profit organization promoting mental health and care for the mentally ill.
Mr. Kranitz's law firm concentrates in business and securities matters, including mergers & acquisitions, private and public securities offerings, investment funds, and corporate organizational matters. The firm's clientele is located around the United States as well as several foreign countries.
Jerry White, GenoMed's Chief Executive Officer, stated that, ``I am honored to announce to our shareholders that Mr. Richard Kranitz has accepted the position as a Director and Corporate Secretary. Mr. Kranitz brings a wealth of knowledge to GenoMed in key areas and is a true asset to the Company and its shareholders. We are confident that we have added another key component to our corporate structure.''
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of disease genes into better patient outcomes as rapidly and as safely as possible. The Company's business model specifically links improved patient outcomes to Company revenues through clinical treatment and genetic diagnoses of diseases.
For additional information please visit genomedics.com and/or contact Craig Hall at 941/366-6677 or email at chall@floridafunds.com.
Contact:
GenoMed Inc., Sarasota
Craig Hall, 941/366-6677
. |
